

## Q3 FY26 Quarterly Activities Report

*Continued YTD margin progression alongside expanded ecosystem and balance sheet flexibility*

**Melbourne, Australia** - Atomos Limited ('ASX:AMS', 'Atomos' or the 'Company') today releases its Appendix 4C and Quarterly Activities Report for the three-month period ended 31 March 2026 (Q3 FY26), along with an update on notable events that have occurred subsequently.

### Highlights Q3'26 Results:


- Q3'26 sales of \$6.6m, down 3% on pcp and below prior quarter, reflecting softer trading conditions in the most seasonally challenging quarter for trading
- Q3'26 EBITDA of \$0.1m<sup>1</sup>, marking three consecutive EBITDA positive quarters
- Q3'26 net operating cash inflow of \$0.8m on cash receipts of \$10.2m, improving from (\$0.9m) in Q2'26
- Cash and cash equivalents of \$1.4m at quarter end supplemented by new debt facility (see below)

### Material post quarter end events:

- New \$10m CBA Business Finance Facility executed; concurrent Monreii facility repricing from 20% to 13% per annum, delivering ~\$0.7m annual interest savings (refer ASX announcements, 10 and 27 April 2026)
- Acquisition of Flanders Scientific completed on 24 April 2026, expanding the Atomos ecosystem into professional reference monitoring (refer ASX announcements, 13 and 27 April 2026)
- Sumo PRO 19, additional ecosystem products and ATOMOSphere update unveiled at NAB Show 2026 (refer ASX announcement, 29 April 2026); seven new and upgraded product releases over the last 12 months

**Commenting on the Q3'26 results, Atomos Managing Director and CEO, Peter Barber, said,** "Q3 trading is seasonally difficult and has also been challenged by softer discretionary spend globally, which has subsequently seen distributors and reseller de-stockings, and this has continued into April. Despite this we continue to actively manage the business and gross margin and net contribution margin remained consistent with 1H'26 results, both materially ahead of pcp, reflecting the structural margin improvement we have been targeting.

1. EBITDA is unaudited and based on Atomos management accounts




The period since has been one of meaningful execution. We released Shogun AV-19 and Ninja RAW in late Q3, completed the Flanders Scientific acquisition in April, and unveiled Sumo PRO 19 and the broader ecosystem update at NAB 2026. Together with the new CBA Facility and the Monreii repricing, Atomos enters Q4 with a broader product set, expanded ecosystem and materially improved balance sheet flexibility.

Trading visibility through Q4 remains uncertain given current global macroeconomic conditions. We remain focused on margin quality, cost discipline, integration of Flanders Scientific, and Q4 product execution."

**Financial Update**


- Q3'26 sales of \$6.6m, broadly in line with pcp (\$6.9m) and adversely affected by distributor and reseller de-stocking, weaker discretionary end-customer demand, and production timing on Shogun AV-19

**Sales (A\$m)**




- Q3'26 EBITDA of \$0.1m<sup>1</sup>, the third consecutive EBITDA positive quarter with lower revenue partly offset by contribution margin uplift and cost discipline

**EBITDA (A\$m)**



- Q3'26 cash receipts of \$10.2m, up 27% on pcp, with the variance to Q3 revenue reflecting collection of receivables from the stronger Q2 trading period
- Q3'26 cash expenses of \$9.4m, lower than prior period reflecting reduced product and operating costs
  - Q3'26 staff, marketing and corporate costs of \$2.9m, broadly consistent with Q1 and Q2 and reinforcing stability of the fixed cost base (FY26 ~\$1.1m per month)
- Q3 net operating cash inflow of \$0.8m reflects strong receipts alongside working capital phasing through the quarter

**Net Operating Cashflow (A\$000)**



- Payments to related parties and their associates of \$384k, relate to remuneration of both executive and non-executive Directors, key management personnel and line fees payable to Monreii Pty Ltd.

### **Operational Update**

In Q3, Atomos released Shogun AV-19 (refer ASX announcement, 13 February 2026), a 19-inch rack-mounted monitor recorder targeting live production and broadcast, and Ninja RAW (refer ASX announcement, 27 February 2026), a compact 5-inch HDR monitor recorder extending the next generation Ninja range. Production timing on Shogun AV-19 shifted initial customer deliveries into Q4.

Post quarter end, the Company unveiled Sumo PRO 19 and a broader product and accessory lineup as well as a significant ATOMOSphere update at NAB Show 2026 (refer ASX announcement, 29 April 2026). Sumo PRO 19 was awarded multiple Best of Show Awards. These releases bring total new and upgraded product releases to seven over the last 12 months.

On 27 April 2026, Atomos completed the acquisition of Flanders Scientific, Inc., expanding the Atomos ecosystem into professional reference monitoring (refer ASX announcements, 13 and 27 April 2026). FSI is expected to generate approximately \$1m of annual EBITDA post synergies and before any revenue growth and is immediately earnings accretive.

## **Funding and Capital Update**

As at 31 March 2026, the Company had cash and cash equivalents of \$1.4m. The Monreii Pty Ltd facility was fully drawn at quarter end.

On 10 April 2026, the Company announced a new \$10m, 3-year Business Finance Facility with Commonwealth Bank of Australia (CBA Facility), which was settled on 27 April 2026 and used in part to fund completion of the Flanders Scientific acquisition (refer ASX announcement, 10 April 2026). Concurrent with the CBA Facility, the Monreii facility was repriced from 20% to 13% per annum, delivering approximately \$0.7m of annual interest savings.

## **Outlook**

Trading conditions through Q3 were softer than expected, driven by weaker discretionary spend reflecting global macroeconomic conditions, continuing distributor and reseller de-stocking, and production timing on Shogun AV-19.

Atomos is not revising guidance at this point but notes a prolonged closure of the Strait of Hormuz and continuation of regional hostilities will likely sustain pressure on consumer and business confidence and make Q4 trading targets more difficult to achieve.

In order to deal with the external shocks Atomos continues to manage costs and does expect a pick-up in sales in Q4 from the recently launched Shogun AV-19, Sumo PRO 19 along with new initiatives such as the Ninja series monitor trade-up program.

This announcement has been authorised for lodgement with ASX by the Board of Directors.

--ENDS--

**For further information, please contact:**

**Peter Barber**

**Managing Director and CEO**

peter@atomos.com

## **Atomos' Interactive Investor Hub**

Our investor hub is an interactive location to engage with the Atomos team on our announcements and updates.

Please go to the Atomos Investor Hub for all market announcements & other news

<https://investors.atomos.com>

## About Atomos

ATOMOS designs pioneering products that transform the way film and video content is made around the world. From our range of hardware devices for monitoring and recording, easy-to-use software tools, and intelligent cloud services, we engineer best-in-class technologies and create products for the next generation of filmmakers.

Through relentless innovation, we simplify your workflow. Whether you record cinema-quality footage, monitor a scene with crystal clear colour accuracy, switch between multiple cameras, or stream a live event with a portable studio, ATOMOS empowers anyone to realize the best possible version of their creative potential.

ATOMOS is based in Melbourne, Australia, with a distributed worldwide team and offices in the USA, Japan, China, UK, and Germany and has a worldwide distribution partner network.

For more information, please visit [www.atomos.com](http://www.atomos.com).

For personal use only



## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Atomos Limited

**ABN**

25 139 730 500

**Quarter ended ("current quarter")**

31 March 2026

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (9 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	10,174	30,706
1.2 Payments for		
(a) research and development	(412)	(1,273)
(b) product manufacturing and operating costs	(5,787)	(19,825)
(c) advertising and marketing	(501)	(1,559)
(d) leased assets	-	-
(e) staff costs	(1,769)	(5,352)
(f) administration and corporate costs	(648)	(2,917)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	3	5
1.5 Interest and other costs of finance paid	(32)	(72)
1.6 Income taxes paid	(215)	(513)
1.7 Government grants and tax incentives	-	-
1.8 Other	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>813</b>	<b>(800)</b>
<i>Note: amounts in this section do not include GST</i>		
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(40)	(286)
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
(f) other non-current assets	(389)	(476)
<b>2.2</b> Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
<b>2.3</b> Cash flows from loans to other entities	-	-
<b>2.4</b> Dividends received (see note 3)	-	-
<b>2.5</b> Other (provide details if material)	-	-
<b>2.6</b> <b>Net cash from / (used in) investing activities</b>	<b>(429)</b>	<b>(762)</b>

<b>3.</b> <b>Cash flows from financing activities</b>		
<b>3.1</b> Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
<b>3.2</b> Proceeds from issue of convertible debt securities	-	-
<b>3.3</b> Proceeds from exercise of options	-	7,878
<b>3.4</b> Transaction costs related to issues of equity securities or convertible debt securities	-	(10)
<b>3.5</b> Proceeds from borrowings	-	2,000
<b>3.6</b> Repayment of borrowings	-	(7,761)
<b>3.7</b> Transaction costs related to loans and borrowings	-	-
<b>3.8</b> Dividends paid	-	-
<b>3.9</b> Other (AASB16 Principal Repayments & Credit Card Repayments, includes Q1 restatement)	(333)	(950)
<b>3.10</b> <b>Net cash from / (used in) financing activities</b>	<b>(333)</b>	<b>1,157</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	1,329	1,813
4.2	Net cash from / (used in) operating activities (item 1.9 above)	813	(800)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(429)	(762)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(333)	1,157
4.5	Effect of movement in exchange rates on cash held	4	(24)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>1,384</b>	<b>1,384</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	901	846
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (Rental Guarantees)	483	483
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>1,384</b>	<b>1,329</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	384
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. <b>Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (Debt Facility*)	10,362	10,362
Other (Corporate Credit Card)	18	18
<b>7.4 Total financing facilities</b>	<b>10,380</b>	<b>10,380</b>
<b>7.5 Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
* On 24 September 2025, we announced an extended \$15.7m loan facility with Monreii Pty Ltd. On 1 December 2025, we announced this facility had been repaid down to \$9.7m following the exercise of 259.8 million ASX-listed options. The facility liability stands at \$10.4m as at 31 March, including all Capitalised Interest. As announced <a href="#">here</a> , the cost of this loan has now been reduced from 20% to 13%. In addition, the Company has received a further \$10.0m of funding from CBA in line with terms announced <a href="#">here</a> .		

8. <b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	813
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,384
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	<b>1,384</b>
8.5 <b>Estimated quarters of funding available (item 8.4, divided by item 8.1)</b>	<b>N/A</b>
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

N/A

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2026



Authorised by: Peter Barber, CEO  
(Name of body or officer authorising release – see note 4)

### Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.